Fulgent Genetics, Inc. FLGT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Laboratory Services | $319.81M+9.4% | $322.22M+13.7% | $315.41M+13.6% | $303.22M+4.3% | $292.45M+1.7% | |
| Therapeutic Development | $534K— | $447K— | $138K— | $0— | $0— | |
| Operating Income by Business | ||||||
| Laboratory Services | -$19.72M— | -$7.51M— | —— | —— | —— | |
| Therapeutic Development | -$20.05M-16.3% | -$19.85M-19.8% | -$19.57M— | -$17.39M— | -$17.25M— | |
| Cost Of Revenue by Business | ||||||
| Laboratory Services | $189.81M+10.7% | $184.96M+9.8% | $178.34M+5.1% | $174.51M+2.4% | $171.42M-0.1% | |
| Therapeutic Development | $13K— | $5K— | $0— | $0— | $0— | |
| Interest Expense Nonoperating by Business | ||||||
| Laboratory Services | $78K— | $75K— | —— | —— | —— | |
| Therapeutic Development | $0— | $0— | $0— | $0— | $0— | |
| Finite Lived Intangible Assets Gross by Business | ||||||
| Laboratory Services | $354.51M+6.6% | $332.45M0.0% | $332.41M0.0% | $332.42M— | $332.41M— | |
| Finite Lived Intangible Assets Net by Business | ||||||
| Laboratory Services | $276.82M-3.1% | $261.94M-10.8% | $269.77M-10.6% | $277.8M— | $285.72M— | |
| Selling And Marketing Expense by Business | ||||||
| Laboratory Services | $44.35M+38.7% | $40.35M+24.8% | $38.67M+17.7% | $35.96M+6.4% | $31.98M-9.5% | |
| Therapeutic Development | $5K— | $5K— | $0— | $0— | $0— | |
| Total Assets by Business | ||||||
| Laboratory Services | $4.34B-4.4% | $4.41B-3.4% | $4.44B-2.9% | $4.5B— | $4.54B— | |
| Therapeutic Development | $446.08M+25.7% | $425.85M+19.9% | $397.55M+11.9% | $354.7M— | $354.75M— | |
| Investment Income Interest by Business | ||||||
| Laboratory Services | $31.55M-1.2% | $30.92M-1.2% | $32.11M+12.3% | $32.32M+24.8% | $31.94M+35.4% | |
| Therapeutic Development | $0— | $0— | $0— | $0— | $0— | |
| Research And Development Expense by Business | ||||||
| Laboratory Services | $23.17M+22.3% | $21.64M+18.8% | $20.07M+8.2% | $19.52M+3.5% | $18.94M+0.3% | |
| Therapeutic Development | $19.23M+18.4% | $19.04M+21.8% | $18.31M+38.4% | $16.45M+44.6% | $16.23M+88.0% | |
| General And Administrative Expense by Business | ||||||
| Laboratory Services | $82.21M+12.2% | $82.78M+19.3% | $80.95M+18.5% | $78.69M+11.2% | $73.3M+0.5% | |
| Therapeutic Development | $1.34M+32.4% | $1.25M+34.5% | $1.4M+73.8% | $936K+22.6% | $1.02M+48.2% | |
| D&A by Business | ||||||
| Laboratory Services | $23.65M+0.6% | $23.55M-2.8% | $23.59M-3.9% | $23.42M-6.5% | $23.51M-6.8% | |
| Therapeutic Development | $550K-18.9% | $571K-17.0% | $610K-13.7% | $669K-6.2% | $678K-3.8% | |
| Allocated Share Based Compensation Expense by Business | ||||||
| Laboratory Services | $30.68M-13.5% | $31.57M-14.6% | $32.85M-11.9% | $34.19M-8.0% | $35.45M-3.6% | |
| Therapeutic Development | $8.25M+2.2% | $8.02M+6.4% | $7.86M+4.7% | $7.73M+3.5% | $8.07M+16.3% | |
| Finite Lived Intangible Assets Accumulated Amortization by Business | ||||||
| Laboratory Services | $99.25M+35.8% | $92.68M+39.2% | $86.13M+43.3% | $79.62M— | $73.1M— | |
| Goodwill by Business | ||||||
| Therapeutic Development | $94.61M+7.2% | $94.36M+7.0% | $91.34M+3.5% | $88.31M— | $88.27M— | |
| Revenue by Geography | ||||||
| Non Us | $26.51M+7.6% | $26.12M+1.9% | $23.83M-5.2% | $23.41M-5.6% | $24.65M+8.3% | |
| Other Countries | $13.66M+1.2% | $13.21M+1.6% | $12.41M-0.9% | $12.33M+6.8% | $13.5M+45.1% | |
| PP&E (Net) by Geography | ||||||
| Non Us | $25.41M+12.0% | $25.72M+23.7% | $25.98M+31.5% | $24.59M— | $22.69M— | |
| Other Countries | $6.59M— | $6.8M— | $7.13M— | $5.59M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Fulgent Genetics, Inc. break its business down?
- Fulgent Genetics, Inc. (FLGT) reports revenue by business across 2 parts — Laboratory Services and Therapeutic Development. Each is extracted from the segment footnotes and tracked over time.
- Where does Fulgent Genetics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Fulgent Genetics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
